A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-Erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study).

Trial Profile

A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-Erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Docetaxel (Primary) ; Erlotinib (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NVALT-10
  • Most Recent Events

    • 28 Aug 2013 Results published in the Annals of Oncology.
    • 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
    • 02 Oct 2012 Patients were enrolled between March 2009 and December 2011 according to the abstract.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top